• Kempharm Inc., of North Liberty, Iowa, disclosed positive results from one of several clinical and nonclinical studies that the company is performing in preparation for its new drug application for KP201 (benzhydrocodone and acetaminophen), which the company anticipates filing in the second quarter of 2014.